Stock Track | Intellia Therapeutics Soars 6.24% in Pre-market on Analyst Bullish Call
Stock Track
Mar 02
Intellia Therapeutics (NTLA) stock soared 6.24% in pre-market trading on Monday, showing significant upward momentum ahead of the regular session.
The surge appears driven by a positive analyst action, with H.C. Wainwright analyst Mitchell Kapoor reiterating a Buy rating on the company and setting a price target of $25.00.
Such analyst endorsements often influence investor sentiment, particularly in pre-market activity, as they provide forward-looking assessments of a company's value and prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.